Theranostic Application of FAPI in Advanced Laryngeal Squamous Cell Carcinoma: 99m Tc-FAPI-46 SPECT/CT Guided 177 Lu-FAPI-2286 Therapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 42149939.
- Also identified by DOI 10.1097/RLU.0000000000006505.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A 47-year-old man with advanced laryngeal squamous cell carcinoma had received chemotherapy but subsequently developed widespread skeletal metastases identified on bone scintigraphy. He underwent 99m Tc-FAPI-46 SPECT/CT, which demonstrated FAPI uptake in primary laryngeal tumor, cervical soft tissue involvement, and extensive skeletal metastases, accurately reflecting the overall disease burden. Due to disease progression despite chemotherapy and for palliative management of bone pain, he was enrolled in a clinical trial and received 177 Lu-FAPI-2286 radioligand therapy. Post-treatment imaging confirmed tracer accumulation in all known disease sites, highlighting the clinical utility of FAPI-based imaging and its theranostic potential in advanced laryngeal carcinoma.
Medical subject headings
- Laryngeal Neoplasms
- Carcinoma, Squamous Cell
- Single Photon Emission Computed Tomography Computed Tomography
- Technetium
- Radioisotopes